pyridinolcarbamate has been researched along with Adenocarcinoma of Lung in 1 studies
Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
Adenocarcinoma of Lung: A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Yu, Z | 1 |
Peng, Y | 1 |
Gao, J | 1 |
Zhou, M | 1 |
Shi, L | 1 |
Zhao, F | 1 |
Wang, C | 1 |
Tian, X | 1 |
Feng, L | 1 |
Huo, X | 1 |
Zhang, B | 1 |
Liu, M | 1 |
Fang, D | 1 |
Ma, X | 1 |
1 other study available for pyridinolcarbamate and Adenocarcinoma of Lung
Article | Year |
---|---|
The p23 co-chaperone is a succinate-activated COX-2 transcription factor in lung adenocarcinoma tumorigenesis.
Topics: Adenocarcinoma of Lung; Carcinogenesis; Cell Transformation, Neoplastic; Cyclooxygenase 2; HSP90 Hea | 2023 |